These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 29288941)

  • 21. Quinazolin-4(3H)-one-Based Hydroxamic Acids: Design, Synthesis and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
    Hieu DT; Anh DT; Hai PT; Thuan NT; Huong LT; Park EJ; Young Ji A; Soon Kang J; Phuong Dung PT; Han SB; Nam NH
    Chem Biodivers; 2019 Apr; 16(4):e1800502. PubMed ID: 30653817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
    Ojha R; Huang HL; HuangFu WC; Wu YW; Nepali K; Lai MJ; Su CJ; Sung TY; Chen YL; Pan SL; Liou JP
    Eur J Med Chem; 2018 Apr; 150():667-677. PubMed ID: 29567459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and antitumor activity of novel diaryl ether hydroxamic acids derivatives as potential HDAC inhibitors.
    Zhu Y; Chen X; Wu Z; Zheng Y; Chen Y; Tang W; Lu T
    Arch Pharm Res; 2012 Oct; 35(10):1723-32. PubMed ID: 23139122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
    Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
    Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and biological evaluation of thiophene-based hydroxamate derivatives as HDACis with antitumor activities.
    Yang F; Han L; Zhao N; Yang Y; Ge D; Zhang H; Chen Y
    Future Med Chem; 2020 Apr; 12(8):655-672. PubMed ID: 32202140
    [No Abstract]   [Full Text] [Related]  

  • 26. Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
    Chao SW; Chen LC; Yu CC; Liu CY; Lin TE; Guh JH; Wang CY; Chen CY; Hsu KC; Huang WJ
    Eur J Med Chem; 2018 Jan; 143():792-805. PubMed ID: 29223096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
    Tazzari V; Cappelletti G; Casagrande M; Perrino E; Renzi L; Del Soldato P; Sparatore A
    Bioorg Med Chem; 2010 Jun; 18(12):4187-94. PubMed ID: 20576572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
    Li X; Hou J; Li X; Jiang Y; Liu X; Mu W; Jin Y; Zhang Y; Xu W
    Eur J Med Chem; 2015 Jan; 89():628-37. PubMed ID: 25462271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.
    Chetan B; Bunha M; Jagrat M; Sinha BN; Saiko P; Graser G; Szekeres T; Raman G; Rajendran P; Moorthy D; Basu A; Jayaprakash V
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3906-10. PubMed ID: 20605448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
    Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
    ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and biological evaluation of 4-anilinothieno[2,3-d]pyrimidine-based hydroxamic acid derivatives as novel histone deacetylase inhibitors.
    Yang W; Li L; Ji X; Wu X; Su M; Sheng L; Zang Y; Li J; Liu H
    Bioorg Med Chem; 2014 Nov; 22(21):6146-55. PubMed ID: 25261927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities.
    Zhao N; Yang F; Han L; Qu Y; Ge D; Zhang H
    Molecules; 2020 Feb; 25(3):. PubMed ID: 32046013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 5-aryl-1,3,4-thiadiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents: synthesis, bioevaluation and docking study.
    Huong TT; Dung do TM; Oanh DT; Lan TT; Dung PT; Loi VD; Kim KR; Han BW; Yun J; Kang JS; Kim Y; Han SB; Nam NH
    Med Chem; 2015; 11(3):296-304. PubMed ID: 25256241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel Pyridine-Based Hydroxamates and 2'-Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity.
    Zwergel C; Di Bello E; Fioravanti R; Conte M; Nebbioso A; Mazzone R; Brosch G; Mercurio C; Varasi M; Altucci L; Valente S; Mai A
    ChemMedChem; 2021 Mar; 16(6):989-999. PubMed ID: 33220015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New benzothiazole/thiazole-containing hydroxamic acids as potent histone deacetylase inhibitors and antitumor agents.
    Tung TT; Oanh DT; Dung PT; Hue VT; Park SH; Han BW; Kim Y; Hong JT; Han SB; Nam NH
    Med Chem; 2013 Dec; 9(8):1051-7. PubMed ID: 23521008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
    Cheng C; Yun F; He J; Ullah S; Yuan Q
    Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
    Luo G; Lin X; Ren S; Wu S; Wang X; Ma L; Xiang H
    Eur J Med Chem; 2021 Dec; 226():113870. PubMed ID: 34610548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of potent histone deacetylase inhibitors with modified phenanthridine caps.
    Fan W; Zhang L; Wang X; Jia H; Zhang L
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):707-718. PubMed ID: 33663315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
    Liu J; Zhou J; He F; Gao L; Wen Y; Gao L; Wang P; Kang D; Hu L
    Eur J Med Chem; 2020 Apr; 192():112189. PubMed ID: 32151834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
    Xie R; Li Y; Tang P; Yuan Q
    Eur J Med Chem; 2018 Jan; 143():320-333. PubMed ID: 29202397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.